Form 4: Protagenic Therapeutics Director Acquires Options

Jennifer Buell, a director at Protagenic Therapeutics, acquired options to purchase 75,000 shares of PTIX common stock on March 25, 2024.

Summary

• On March 25, 2024, Jennifer Buell, a director of Protagenic Therapeutics, acquired options to purchase 75,000 shares of the company's common stock.
• The exercise price of these options is $1.74.
• 50,000 of the options are fully exercisable starting March 25, 2026.
• The remaining 25,000 options become exercisable upon the consummation of a corporate partnership before December 31, 2026; otherwise, they will not be exercisable.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports the acquisition of options by a director. The contingent nature of some options adds a slight element of uncertainty.

Risks

• 25,000 of the options are contingent on the company entering into a corporate partnership before December 31, 2026, which may not occur.

Future Outlook

The exercisability of 25,000 options is contingent on Protagenic Therapeutics entering into a corporate partnership before December 31, 2026, which introduces uncertainty.

Industry Context

This filing reflects insider activity, which is closely monitored by investors for signals about management's confidence in the company's prospects. Option grants are a common form of executive compensation in the biotech industry.

Stakeholder Impact

• The acquisition of options by a director may signal confidence in the company's future, potentially impacting shareholder sentiment.

Key Dates

Keywords

Protagenic Therapeutics, PTIX, Jennifer Buell, options, director, beneficial ownership, Form 4, acquisition